(News Bulletin 247) – GSK publishes a turnover of £6.9 billion for the 1st quarter, marking a decline of 8% at constant exchange rates compared to the 1st quarter of the previous financial year. Excluding the decline in covid contracts, turnover would increase by 10%, underlines the laboratory.
Quarterly adjusted operating profit came out at £2.09bn, stable at constant exchange rates and slightly beating consensus expectations.
Adjusted EPS came out at 37 pence, up 7% at constant exchange rates.
“We have started 2023 well, with excellent performance in vaccines, specialty medicine and general medicine. We are very focused on our upcoming launches, including our potential RSV vaccine for the elderly, and on continuing to strengthen our pipeline,” commented Emma Walmsley, Chief Executive Officer.
In this context, GSK confirms its forecasts for the 2023 financial year and announces a dividend of 14 pence for the past quarter. The laboratory is targeting a dividend of 56.5 pence per share for the full year.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
